Literature DB >> 23991920

Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?

Leandro Cerchietti, Ari Melnick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23991920      PMCID： PMC4083750          DOI： 10.1586/17474086.2013.826928

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  17 in total

Review 1.  Roles of BCL6 in normal and transformed germinal center B cells.

Authors:  Katia Basso; Riccardo Dalla-Favera
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

2.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

3.  Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

Authors:  Stella Maris Ranuncolo; Jose M Polo; Jamil Dierov; Michael Singer; Tracy Kuo; John Greally; Roland Green; Martin Carroll; Ari Melnick
Journal:  Nat Immunol       Date:  2007-06-10       Impact factor: 25.606

4.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

5.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

6.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

Authors:  Jose M Polo; Tania Dell'Oso; Stella Maris Ranuncolo; Leandro Cerchietti; David Beck; Gustavo F Da Silva; Gilbert G Prive; Jonathan D Licht; Ari Melnick
Journal:  Nat Med       Date:  2004-11-07       Impact factor: 53.440

7.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

Review 8.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05

9.  BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Authors:  Przemyslaw Juszczynski; Linfeng Chen; Evan O'Donnell; Jose M Polo; Stella M Ranuncolo; Riccardo Dalla-Favera; Ari Melnick; Margaret A Shipp
Journal:  Blood       Date:  2009-10-23       Impact factor: 22.113

10.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.

Authors:  Grant D Barish; Ruth T Yu; Malith S Karunasiri; Diana Becerra; Jason Kim; Tiffany W Tseng; Li-Jung Tai; Matthias Leblanc; Cody Diehl; Leandro Cerchietti; Yury I Miller; Joseph L Witztum; Ari M Melnick; Alexander L Dent; Rajendra K Tangirala; Ronald M Evans
Journal:  Cell Metab       Date:  2012-03-29       Impact factor: 27.287
View more
  12 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Authors:  Thibault Dupont; Shao Ning Yang; Jayeshkumar Patel; Katerina Hatzi; Alka Malik; Wayne Tam; Peter Martin; John Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Oncotarget       Date:  2016-01-19

3.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Authors:  Mariano G Cardenas; Wenbo Yu; Wendy Beguelin; Matthew R Teater; Huimin Geng; Rebecca L Goldstein; Erin Oswald; Katerina Hatzi; Shao-Ning Yang; Joanna Cohen; Rita Shaknovich; Kenno Vanommeslaeghe; Huimin Cheng; Dongdong Liang; Hyo Je Cho; Joshua Abbott; Wayne Tam; Wei Du; John P Leonard; Olivier Elemento; Leandro Cerchietti; Tomasz Cierpicki; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

4.  BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).

Authors:  Yanhui Cai; Meagan A Watkins; Fengtian Xue; Yong Ai; Huiming Cheng; Cecily C Midkiff; Xiaolei Wang; Xavier Alvarez; Adi Narayana Reddy Poli; Joseph M Salvino; Ronald S Veazey; Luis J Montaner
Journal:  J Med Primatol       Date:  2019-10-01       Impact factor: 0.667

Review 5.  The curious origins of angioimmunoblastic T-cell lymphoma.

Authors:  José R Cortés; Teresa Palomero
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

Review 6.  Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.

Authors:  Kieron Dunleavy; Mark Roschewski; Wyndham H Wilson
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

Review 7.  Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2014-04       Impact factor: 2.990

8.  miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.

Authors:  Qian Fan; Xiangrui Meng; Hongwei Liang; Huilai Zhang; Xianming Liu; Lanfang Li; Wei Li; Wu Sun; Haiyang Zhang; Ke Zen; Chen-Yu Zhang; Zhen Zhou; Xi Chen; Yi Ba
Journal:  Protein Cell       Date:  2016-11-04       Impact factor: 14.870

9.  BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.

Authors:  Yanhui Cai; Adi Narayana Reddy Poli; Surya Vadrevu; Kwasi Gyampoh; Colin Hart; Brian Ross; Matt Fair; Fengtian Xue; Joseph M Salvino; Luis J Montaner
Journal:  Eur J Immunol       Date:  2021-09-16       Impact factor: 5.532

10.  High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.

Authors:  Cheng-Chih Tsai; Yung-Cheng Su; Oluwaseun Adebayo Bamodu; Bo-Jung Chen; Wen-Chiuan Tsai; Wei-Hong Cheng; Chii-Hong Lee; Shu-Min Hsieh; Mei-Ling Liu; Chia-Lang Fang; Huan-Tze Lin; Chi-Long Chen; Chi-Tai Yeh; Wei-Hwa Lee; Ching-Liang Ho; Shiue-Wei Lai; Huey-En Tzeng; Yao-Yu Hsieh; Chia-Lun Chang; Yu-Mei Zheng; Hui-Wen Liu; Yun Yen; Jacqueline Whang-Peng; Tsu-Yi Chao
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.